Florkiewicz R Z, Anchin J, Baird A
PRIZM Pharmaceuticals, San Diego, California 92121, USA.
J Biol Chem. 1998 Jan 2;273(1):544-51. doi: 10.1074/jbc.273.1.544.
Basic fibroblast growth factor (FGF-2) is one of a select group of proteins that can exit cells through an alternate, endoplasmic reticulum/Golgi apparatus independent exocytic pathway. This alternate pathway has been termed protein export. In an attempt to better understand this process, we have identified a family of related compounds, "cardenolides," that inhibit FGF-2 export. The cardenolides inhibit FGF-2 export in a time and concentration dependent fashion. Inhibition of FGF-2 export is specific in that the cardenolides have no effect on conventional protein secretion as measured by their inability to block release of the secreted protein human chorionic gonadotropin-alpha. Because cardenolides are known to inhibit ion transport activity mediated by Na+,K+-ATPase, we investigated whether there are functional interactions between FGF-2 and their only known molecular target: the alpha-subunit of Na+, K+-ATPase. Export of FGF-2 from COS-1 cells is selectively inhibited when co-transfected with expression vectors encoding the alpha-subunit and FGF-2. Moreover, antibodies to the alpha-subunit specifically co-immunoprecipitate FGF-2 along with the alpha-subunit while conversely, antibodies to FGF-2 specifically co-immunoprecipitate the alpha-subunit along with FGF-2. Finally, the ion transporting activities of the Na+,K+-ATPase can be uncoupled from protein export. Varying the external concentration of K+ has little effect on export of FGF-2. Taken together, these data: 1) identify a novel activity for cardenolides; 2) suggest a previously unknown role for the alpha-subunit of Na+, K+-ATPase in FGF-2 export; and 3) raise the possibility that the alpha-subunit itself may be an integral component of this alternate exocytic pathway mediating translocation of cytosolic FGF-2 to the cell surface.
碱性成纤维细胞生长因子(FGF - 2)是一类特定蛋白质中的一种,这类蛋白质能够通过一种独立于内质网/高尔基体的替代性胞吐途径离开细胞。这种替代性途径被称为蛋白质输出。为了更好地理解这一过程,我们鉴定出了一类相关化合物“强心甾类”,它们能够抑制FGF - 2的输出。强心甾类以时间和浓度依赖的方式抑制FGF - 2的输出。FGF - 2输出的抑制具有特异性,因为强心甾类对传统蛋白质分泌没有影响,这通过它们无法阻断分泌蛋白人绒毛膜促性腺激素α的释放得以衡量。由于已知强心甾类会抑制由Na⁺,K⁺ - ATP酶介导的离子转运活性,我们研究了FGF - 2与其唯一已知分子靶点:Na⁺,K⁺ - ATP酶的α亚基之间是否存在功能相互作用。当与编码α亚基和FGF - 2的表达载体共转染时,COS - 1细胞中FGF - 2的输出会被选择性抑制。此外,针对α亚基的抗体能特异性地将FGF - 2与α亚基一起进行共免疫沉淀,反之,针对FGF - 2的抗体能特异性地将α亚基与FGF - 2一起进行共免疫沉淀。最后,Na⁺,K⁺ - ATP酶的离子转运活性可以与蛋白质输出解偶联。改变外部K⁺浓度对FGF - 2的输出影响很小。综上所述,这些数据:1)确定了强心甾类的一种新活性;2)表明Na⁺,K⁺ - ATP酶的α亚基在FGF - 2输出中具有先前未知的作用;3)增加了α亚基本身可能是介导胞质FGF - 2转运到细胞表面的这种替代性胞吐途径的一个组成部分的可能性。